Clinical Research Directory
Browse clinical research sites, groups, and studies.
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery
Sponsor: The University of Hong Kong
Summary
This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery. Recruited patients will be randomized in a 2:1 ratio to receive single subcutaneous dose of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RAs) 1 to 14 days prior to surgery or receive routine care. Dulaglutide (Trulicity; Eli Lilly, USA) is chosen as GLP-1 Receptor Agonists investigational drug for this study. Apart from peri-operative routine care, all recruited subjects will undergo physical, respiratory and cardiac assessments including electrocardiography and blood check including cardiac enzymes. Myocardial injury, cardiovascular outcomes and safety will be assessed and evaluated for efficacy and safety of this prophylactic measurement for the reduction of myocardial injury after non-cardiac surgery.
Official title: Glucagon-like Peptide-1 Receptor Agonist for Reduction of Myocardial Injury After Non-Cardiac Surgery
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
372
Start Date
2024-03-20
Completion Date
2028-12-31
Last Updated
2025-08-22
Healthy Volunteers
No
Conditions
Interventions
Dulaglutide 0.75mg subcutaneous injection
Subject randomized into treatment group will receive single subcutaneous dose of Dulaglutide 0.75mg 1 to 14 days prior to surgery
Locations (3)
Duchess of Kent Children's Hospital at Sandy Bay
Hong Kong, Hong Kong SAR, China
Queen Mary Hospital
Hong Kong, Hong Kong SAR, China
Tung Wah Hospital
Hong Kong, Hong Kong SAR, China